Loading
Surgeon who led CARMENA, the trial that showed most metastatic kidney cancer patients do not benefit from removing the kidney.
Arnaud Méjean (Paris) was principal investigator of CARMENA, which showed sunitinib alone was non-inferior to cytoreductive nephrectomy followed by sunitinib in intermediate and poor-risk metastatic renal cell carcinoma, ending routine upfront nephrectomy in the targeted therapy era. His work redefined the role of surgery in advanced kidney cancer and is being revisited in the immunotherapy era.
| Title | Journal | Year |
|---|---|---|
| Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma (CARMENA) | NEJM | 2018 |
| Cytoreductive nephrectomy in metastatic renal cancer: update on the CARMENA trial | European Urology | 2021 |
Shares European Urology, Robotic & minimally invasive surgery and the tag surgery.
Shares Robotic & minimally invasive surgery and the tag surgery.
Shares Robotic & minimally invasive surgery and the tag surgery.
Shares Renal cell carcinoma and the tag rcc.
Shares Robotic & minimally invasive surgery and the tag surgery.
Shares Robotic & minimally invasive surgery and the tag surgery.
Shares Renal cell carcinoma and the tag rcc.
Shares Robotic & minimally invasive surgery and the tag surgery.